











40. Robien K, Ulrich CM. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. *Am J Epidemiol.* 2003;157:571-82.
41. van der Put NM, Steegers-Theunissen RP, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. *Lancet.* 1995; 346:1070-1.
42. Chiusolo P, Reddiconto G, Casorelli I, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. *Ann Oncol.* 2002; 13:1915-8.
43. Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. *Pharmacogenetics.* 2002;12:183-90.
44. Taub JW, Matherly LH, Ravindranath Y, et al. Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. *Leukemia.* 2002; 16:764-5.
45. Ulrich CM, Robien K, Sparks R. Pharmacogenetics and folate metabolism -- a promising direction. *Pharmacogenomics.* 2002; 3: 299-313.
46. Gorlick R, Bertino JR: Clinical pharmacology and resistance to dihydrofolate reductase inhibitors. In : *Antifolate Drugs in Cancer Therapy.* Jackman AL (Ed.), Humana, Totowa, NJ, USA. 37-47. 1999.
47. Krajcinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and -MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. *Pharmacogenomics J.* 2004; 4:66-72.
48. Toffoli G, Russo A, Innocenti F, et al. Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. *Int J Cancer.* 2003; 3:294-9.
49. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. *Crit Rev Biochem Mol Biol.* 1995; 30: 445-600.
50. Tsuchida S, Sato K. Glutathione transferases and cancer. *Crit Rev Biochem Mol Biol.* 1992;27:337-84.
51. Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. *Blood.* 1997 Mar 1;89(5):1701-7.
52. Strange RC, Spiteri MA, Ramachandran S, et al. Glutathione-S-transferase family of enzymes. *Mutat Res.* 2001; 482:21-6.
53. Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. *Biochem J.* 1994;300:271-6.
54. Board PG, Webb GC, Coggan M. Isolation of a cDNA clone and localization of the human glutathione S-transferase 3 genes to chromosome bands 11q13 and 12q13-14. *Ann Hum Genet.* 1989; 53: 205-13.
55. Board P, Coggan M, Johnston P, et al. Genetic heterogeneity of the human glutathione transferases: a complex of gene families. *Pharmacol Ther.* 1990;48:357-69.
56. Zimniak P, Nanduri B, Pikula S, et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. *Eur J Biochem.* 1994; 224: 893-9.
57. Anderer G, Schrappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. *Pharmacogenetics.* 2000;10: 715-26.
58. Stanulla M, Schaffeler E, Arens S, et al. GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. *Int J Hematol.* 2005; 81:39-44.